Credit Suisse’s Carisma Therapeutics CARM Stock Holding History

Credit Suisse’s Portfolio CARM Stock Details CARM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Hold	0	–	-$1	–	3332
2022 Q4	–	Hold	0	–	–	–	3913
2022 Q3	–	Hold	0	–	–	–	4056
2022 Q2	–	Hold	0	–	–	–	3957
2020 Q1	–	Sell	-12,563	Closed	-$261K	–	4002
2019 Q4	$261K	Buy	+12,563	New	+$289K	﹤0.01%	3881
2017 Q1	–	Sell	-743	Closed	-$28K	–	3821
2016 Q4	$28K	Buy	+743	New	+$32.7K	﹤0.01%	4057
2015 Q3	–	Sell	-661	Closed	-$37K	–	4278
2015 Q2	$37K	Buy	+661	New	+$93.3K	﹤0.01%	4479

Other funds holding CARM

TOTUOP

Trustees of The University of Pennsylvania Philaldelphia, Pennsylvania $104M AUM

TGA

TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

DCM

Deuterium Capital Management Clearwater, Florida $92.4M AUM 35% 1-Year Est. Return

WIM

Wittenberg Investment Management Carlisle, Massachusetts $292M AUM 36.12% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Credit Suisse's CARM Position: Q1 2023 in Review

Credit Suisse held its Carisma Therapeutics (CARM) position steady in Q1 2023 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #3332.

Credit Suisse first reported a position in CARM in Q2 2015 and has held it in 3 quarters since. The position peaked at $261K in Q4 2019. 37 funds tracked by Wall St. Rank hold CARM as of Q1 2023.

Credit Suisse held 0 shares of Carisma Therapeutics worth $0 as of Q1 2023.
Credit Suisse left its Carisma Therapeutics share count unchanged in Q1 2023.
Carisma Therapeutics made up ﹤0.01% of Credit Suisse's portfolio in Q1 2023, its #3332 holding.
Credit Suisse first reported a position in Carisma Therapeutics in Q2 2015 and has held it in 3 quarters since.
Credit Suisse's Carisma Therapeutics position peaked at $261K in Q4 2019.
37 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q1 2023.

Based on Credit Suisse's 13F filing for Q1 2023, filed 10 May 2023.